Six Arizona startups driving biosciences forward in 2024

Arizona-based bioscience companies developing blood tests to diagnose cancer and other diseases more quickly and accurately, AI tools to automate lab work, and an alternative way to treat itchiness in dogs have been selected for the 2024 Flinn Foundation Bioscience Entrepreneurship Program.  Four of the six early-stage companies representing the 11th cohort of the program are based in Tucson and two are based in the Phoenix area, including one in Carefree.Continue reading

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient’s Bedside

  • The test, run on Abbott’s portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion
  • The test produces lab-quality results in 15 minutes
  • Clinicians are now able to get a result at the patient’s bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency room
  • The test can be used to help evaluate patients up to 24 hours after injury

Continue reading

What is OTEF?

You’ve probably heard of AZAdvances, but do you know about OTEF?   The Opportunity Through Entrepreneurship Foundation (OTEF) is the the 501c3 public charity that houses AZAdvances. Continue reading

C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research

TUCSON, Ariz., March 28, 2024 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.Continue reading